

1 Article

2 Tailoring Glioblastoma Treatment for Frail Populations: 3 Insights from Genomic and Clinical Data

4 Masab Mansoor^{1*}, Andrew Ibrahim², and Kashif Ansari³

5 ¹ Edward Via College of Osteopathic Medicine; mmansoor@vcom.edu
6 ² Texas Tech University Health Science Center; andrew.Ibrahim@ttuhsc.edu
7 ³ East Houston Medical Center, Department of Oncology; kansari@ehoftexas.com
8
9 * Correspondence: mmansoor@vcom.edu

10 **Simple Summary:** Glioblastoma is an aggressive brain cancer that disproportionately affects older
11 adults, a group often excluded from clinical trials. This study aims to examine how treatment
12 approaches, such as radiation therapy and tumor characteristics, influence survival outcomes in
13 glioblastoma patients aged 65 and older. By analyzing clinical and genomic data, we hope to
14 identify factors that may improve treatment strategies and outcomes for this vulnerable
15 population. Our findings could help guide healthcare professionals in making more personalized
16 and effective treatment decisions for older patients, potentially improving their quality of life and
17 survival.

18 **Abstract: Background/Objectives:** Glioblastoma is the most common primary malignant brain
19 tumor in adults, with a particularly high incidence among individuals aged 65 and older. Older
20 patients often experience worse outcomes due to limited treatment options, comorbidities, and
21 frailty. This study investigates the impact of radiation therapy and genomic factors on survival
22 outcomes in older glioblastoma patients, aiming to inform treatment strategies for this vulnerable
23 population. **Methods:** We analyzed clinical and genomic data from 109 glioblastoma patients aged
24 65 and older, obtained from The Cancer Genome Atlas (TCGA). Kaplan-Meier survival analysis
25 was performed to assess the impact of radiation therapy on survival. Correlations between
26 genomic features, including mutation count, tumor mutational burden, and aneuploidy score, and
27 overall survival were examined. Descriptive statistics were used to summarize patient
28 demographics and treatment patterns. **Results:** Radiation therapy was associated with a higher
29 mean survival (10.3 months) compared to patients who did not receive radiation (6.2 months).
30 Genomic factors, such as mutation count and tumor mutational burden, showed weak negative
31 correlations with survival. Despite the overall poor prognosis, radiation therapy appeared to
32 modestly improve survival in this cohort. **Conclusions:** Our findings highlight the potential
33 benefits of radiation therapy for older glioblastoma patients, even in the context of frailty and
34 comorbidities. Further research is needed to explore how genomic markers can inform
35 personalized treatment strategies and improve outcomes in this population.

36

37 **Keywords:** glioblastoma; geriatric oncology; radiation therapy
38

39

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81

1. Introduction

Glioblastoma (GBM) stands as the most prevalent and aggressive primary malignant brain tumor in adults, with a median survival of approximately 12 to 15 months despite intensive treatment efforts [1]. The incidence of GBM notably increases with age, particularly affecting individuals over 65 years. This demographic shift is significant, as the aging population is expanding globally, leading to a higher prevalence of GBM among the elderly. Treating GBM in older adults presents unique challenges. Factors such as decreased functional status, comorbidities, and increased susceptibility to treatment-related toxicities often result in less aggressive therapeutic approaches for this group [2]. Consequently, survival outcomes in elderly patients are generally poorer compared to their younger counterparts [3].

Radiation therapy remains a cornerstone in GBM management [4,5]. However, its efficacy and tolerability in the elderly population are subjects of ongoing debate [6]. Some studies suggest that hypofractionated radiation therapy, which delivers higher doses over fewer sessions, may offer comparable survival benefits with reduced side effects. Yet, the optimal radiation regimen for older patients continues to be a matter of investigation [7]. In addition to treatment modalities, genomic factors such as mutation count and tumor mutational burden (TMB) have emerged as potential prognostic indicators in GBM [8]. Understanding the relationship between these molecular characteristics and patient outcomes could pave the way for personalized treatment strategies, particularly in the context of an aging patient population [9].

This study aims to evaluate the impact of radiation therapy and specific genomic features on survival outcomes in GBM patients aged 65 and older. By analyzing clinical and molecular data, we seek to identify factors that could inform tailored therapeutic approaches, ultimately improving the prognosis and quality of life for this vulnerable population.

2. Materials and Methods

2.1. Study Design and Data Source

This retrospective cohort study analyzed clinical and genomic data from The Cancer Genome Atlas (TCGA) Glioblastoma Multiforme (GBM) dataset. The dataset was accessed via cBioPortal and included 109 patients aged 65 and older [10-12]. The study complied with TCGA data usage policies.

2.2. Patient Selection

Patients with a confirmed diagnosis of glioblastoma and available clinical and genomic data were included. Exclusion criteria included incomplete survival data or age below 65 years.

2.3. Clinical Variables

Clinical data included age at diagnosis, sex, overall survival (months), and radiation therapy status (Yes/No). Radiation therapy information was extracted to analyze its association with survival outcomes.

2.4. Genomic Analysis

82 Key genomic variables analyzed included mutation count, tumor mutational burden
83 (TMB), aneuploidy score, and fraction genome altered. These variables were correlated
84 with overall survival to identify potential prognostic markers.

85 2.5. Statistical Analysis

86 Kaplan-Meier survival analysis was used to evaluate the impact of radiation therapy on
87 overall survival. Correlations between genomic variables and survival were assessed
88 using Pearson's correlation coefficient. Descriptive statistics were calculated for
89 demographic and clinical characteristics.

90 2.6. Ethical Considerations

91 This study utilized publicly available de-identified data and did not require additional
92 ethical approval. Data were handled in compliance with TCGA policies.

93 2.7. Data Availability

94 The dataset used in this study is publicly available through cBioPortal
95 (<https://www.cbioportal.org/>). No new datasets were generated during this study.

96 3. Results


97 This section may be divided by subheadings. It should provide a concise and
98 precise description of the experimental results, their interpretation, as well as the
99 experimental conclusions that can be drawn.

100 3.1. Patient Characteristics

- 101 • The study cohort included 109 patients aged 65 and older, with a mean diagnosis
102 age of 73 years (range: 65–89).
- 103 • Males comprised 57% of the cohort, while 43% were female.
- 104 • Radiation therapy was administered to 64% of patients, while the remaining 36%
105 did not receive radiation.

106 3.2. Survival Outcomes

- 107 • Patients receiving radiation therapy demonstrated a mean overall survival of 10.3
108 months compared to 6.2 months in those who did not receive radiation (Figure 1).




109 **Figure 1.** Kaplan-Meier Survival Curve. Kaplan-Meier survival curves comparing
110 overall survival in glioblastoma patients aged 65 and older based on radiation

111 therapy status. Patients receiving radiation therapy exhibited a higher survival
112 probability over time compared to those who did not receive radiation therapy.
113

- 114 • Kaplan-Meier survival analysis revealed a statistically significant improvement in
115 survival associated with radiation therapy ($p < 0.05$).

116 3.3. Genomic Correlates of Survival



- 117 • Mutation count: $r = -0.11$ (Figure 2)

118 **Figure 2.** Correlation of Mutation Count with Overall Survival. Scatter plot
119 illustrating the relationship between mutation count and overall survival in
120 glioblastoma patients aged 65 and older. The weak negative correlation ($r = -0.11$)
121 suggests that higher mutation counts may be associated with slightly reduced
122 survival.
123

- 124 • Tumor mutational burden (TMB): $r = -0.11$
125 • Aneuploidy score: $r = -0.03$
126 • Fraction genome altered: $r = -0.07$

127 3.4. Genomic Correlates of Survival

- 128 • Males demonstrated a slightly higher mean survival (8.5 months) compared to
129 females (7.8 months), though this difference was not statistically significant.
130 • Patients with a high mutation count (≥ 65 mutations) exhibited a mean survival of
131 7.5 months compared to 9.0 months in those with lower mutation counts.

132 4. Discussion

133 This study highlights the importance of tailoring treatment approaches for
134 glioblastoma (GBM) in older adults. Our findings demonstrate that radiation therapy
135 provides a survival benefit for patients aged 65 and older, even in the context of
136 advanced age and potential frailty. These results align with previous studies
137 emphasizing the role of radiation therapy in improving outcomes for elderly GBM
138 patients [13,14].

139 The observed survival benefit with radiation therapy underscores the need for
140 careful consideration of treatment regimens in this population. While hypofractionated
141 radiation protocols have been suggested as an effective alternative to standard regimens,
142 further studies are needed to identify the optimal approach that balances efficacy and
143 tolerability [15,16].

144 Our analysis of genomic factors revealed weak negative correlations between
145 mutation count, tumor mutational burden (TMB), and survival. These findings are
146 consistent with previous studies indicating that high mutation burdens may reflect
147 tumor aggressiveness rather than therapeutic responsiveness [17]. However, key
148 prognostic markers such as IDH1 mutations and MGMT promoter methylation, which
149 are associated with improved survival, were not available in this dataset [18]. Future
150 studies should incorporate these molecular markers to better stratify risk and inform
151 treatment decisions.

152 The limitations of this study include its retrospective design and reliance on
153 publicly available data, which may not capture all relevant clinical variables, such as
154 performance status or comorbidities. Additionally, the relatively small sample size limits
155 the generalizability of our findings. Prospective studies with larger cohorts are
156 warranted to validate these results and explore additional factors influencing survival in
157 elderly GBM patients.

158 5. Conclusions

159 This study emphasizes the importance of radiation therapy in extending survival
160 for older glioblastoma (GBM) patients, even in the context of advanced age and frailty.
161 While our findings suggest a modest survival benefit from radiation therapy, the weak
162 correlations between genomic factors and survival highlight the complexity of GBM
163 biology in elderly populations.

164 Further research is needed to integrate clinical and genomic data into personalized
165 treatment strategies, particularly for frail patients who may be unable to tolerate
166 aggressive therapies. Expanding prospective studies and incorporating emerging
167 molecular markers will be critical in improving outcomes for this vulnerable group.

168 **Author Contributions:** Both authors contributed equally to this research.

169 **Funding:** This research received no external funding.

170 **Institutional Review Board Statement:** Ethical review and approval were waived for this study
171 due to only using retrospective, publicly available, deidentified data.

172 **Informed Consent Statement:** Patient consent was waived because this research solely uses
173 retrospective, publicly available, deidentified data.

174 **Data Availability Statement:** Data obtained from <https://www.cbioportal.org>.

175 **Conflicts of Interest:** The authors declare no conflicts of interest.

176 177 References

- 178 1. Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. *CIA*. 2014;9:357-367.
179 doi:[10.2147/CIA.S44259](https://doi.org/10.2147/CIA.S44259)
- 180 2. Ladomersky E, Scholtens DM, Kocherginsky M, et al. The Coincidence Between Increasing Age, Immunosuppression, and the
181 Incidence of Patients With Glioblastoma. *Front Pharmacol*. 2019;10. doi:[10.3389/fphar.2019.00200](https://doi.org/10.3389/fphar.2019.00200)
- 182 3. Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. *Cancer Treatment Reviews*.
183 2013;39(4):350-357. doi:[10.1016/j.ctrv.2012.05.008](https://doi.org/10.1016/j.ctrv.2012.05.008)
- 184 4. Desideri I, Nardone V, Morelli I, Gagliardi F, Minniti G. Radiation Oncology in Glioblastoma (GBM). In: Lopci E, Mansi L,
185 eds. *Advanced Imaging and Therapy in Neuro-Oncology*. Springer Nature Switzerland; 2024:101-136. doi:[10.1007/978-3-031-59341-
186 3_7](https://doi.org/10.1007/978-3-031-59341-3_7)
- 187 5. Corso CD, Bindra RS, Mehta MP. The role of radiation in treating glioblastoma: here to stay. *J Neurooncol*. 2017;134(3):479-485.
188 doi:[10.1007/s11060-016-2348-x](https://doi.org/10.1007/s11060-016-2348-x)
- 189 6. Hau E, Shen H, Clark C, Graham PH, Koh ES, L. McDonald K. The evolving roles and controversies of radiotherapy in the
190 treatment of glioblastoma. *Journal of Medical Radiation Sciences*. 2016;63(2):114-123. doi:[10.1002/jmrs.149](https://doi.org/10.1002/jmrs.149)
- 191 7. Management of glioblastoma in older adults - UpToDate. Accessed January 22, 2025.
192 https://www.uptodate.com/contents/management-of-glioblastoma-in-older-adults?utm_source=chatgpt.com
- 193 8. Wang L, Ge J, Lan Y, et al. Tumor mutational burden is associated with poor outcomes in diffuse glioma. *BMC Cancer*.
194 2020;20(1):213. doi:[10.1186/s12885-020-6658-1](https://doi.org/10.1186/s12885-020-6658-1)
- 195 9. Hwang M, Jiang Y. Personalization in digital health interventions for older adults with cancer: A scoping review. *Journal of
196 Geriatric Oncology*. 2023;14(8):101652. doi:[10.1016/j.jgo.2023.101652](https://doi.org/10.1016/j.jgo.2023.101652)

- 197 10. Cerami et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data.
198 Cancer Discovery. May 2012 2; 401. [PubMed](#).
- 199 11. Gao et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* 6, p11
200 (2013). [PubMed](#).
- 201 12. de Bruijn et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE
202 Biopharma Collaborative in cBioPortal. *Cancer Res* (2023). [PubMed](#).
- 203 13. Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. *Cancer.* 2016;122(2):189-197.
204 doi:[10.1002/cncr.29742](https://doi.org/10.1002/cncr.29742)
- 205 14. Yovino S, Grossman SA. Treatment of Glioblastoma in “Elderly” Patients. *Curr Treat Options in Oncol.* 2011;12(3):253-262.
206 doi:[10.1007/s11864-011-0158-0](https://doi.org/10.1007/s11864-011-0158-0)
- 207 15. Kaul D, Florange J, Badakhshi H, et al. Accelerated hyperfractionation plus temozolomide in glioblastoma. *Radiat Oncol.*
208 2016;11(1):70. doi:[10.1186/s13014-016-0645-3](https://doi.org/10.1186/s13014-016-0645-3)
- 209 16. Yu VY, Nguyen D, O’Connor D, et al. Treating Glioblastoma Multiforme (GBM) with super hyperfractionated radiation
210 therapy: Implication of temporal dose fractionation optimization including cancer stem cell dynamics. *PLOS ONE.*
211 2021;16(2):e0245676. doi:[10.1371/journal.pone.0245676](https://doi.org/10.1371/journal.pone.0245676)
- 212 17. Jang B, Yoon D, Lee JY, et al. Integrative multi-omics characterization reveals sex differences in glioblastoma. *Biol Sex Differ.*
213 2024;15(1):23. doi:[10.1186/s13293-024-00601-7](https://doi.org/10.1186/s13293-024-00601-7)
- 214 18. Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma:
215 refining the approach based on emerging evidence and current challenges. *Neuro Oncol.* 2019;21(2):167-178.
216 doi:[10.1093/neuonc/nyy132](https://doi.org/10.1093/neuonc/nyy132)
217
218